Friday, November 4, 2011

Multiple Sclerosis (Biogen-Idec)

Biogen-Idec's BG-12 Shines At the Top of the Charts in the Treatment of Relapsing-Remitting Multiple Sclerosis (From Marketwatch.com)

BG-12 Beats Teva's Copaxone in Biogen-Idec's CONFIRM Trial

The top-line results of DEFINE trial were replicated in the second pivotal Phase III trial CONFIRM, which significantly reduced annualized relapse rate (ARR) by 44 percent for BID (p< 0.0001) and by 51 percent for TID (p< 0.0001) versus placebo at two years.

It is believed that BG-12 has dual anti-inflammatory and neuroprotective effects via the Nrf2 pathway.

The results from the CONFIRM study showed that BG-12 beats Teva's Copaxone, which reduced the ARR by only 29 percent (p< 0.02) compared with placebo at two years.

With two robust and positive pivotal clinical trials that exposed BG-12 to over 2,600 patients, the drug is well positioned as a top MS therapy of choice and a formidable competitor to Gilenya from Novartis, which gained FDA approval in September 2010.











No comments:

Post a Comment